Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985728 | 0.93 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL17338022 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL24760895 | 0.76 | PKM (0.35) | HSD11B1PKM | |
| SCHEMBL12765556 | 0.75 | GRIN2D (0.39) | HSD11B1PKM | |
| SCHEMBL9985135 | 0.74 | PTGS2 (0.39) | HSD11B1 | |
| SCHEMBL1557250 | 0.73 | HSD11B1 (0.35) | HSD11B1PKM | |
| SCHEMBL719792 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL5514094 | 0.71 | ALDH1A1 (0.38) | — | |
| SCHEMBL2264953 | 0.69 | PKM (0.39) | HSD11B1PKM | |
| SCHEMBL16374917 | 0.69 | PKM (0.39) | HSD11B1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303845-B1 | Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8524737-B2 | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524737-B2 | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524737-B2 | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-20110190340-A1 | BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190340-A1 | BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2303845-A2 | BI-AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINE DERIVATIVES AS RHO KINASE INHIBITORS | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009156092-A2 | BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190340-A1 | BI- AND POLYCYCLIC SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | RHOT2, MYLK2, ROCK2 | HSD11B1 2886/4885PKM 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.